Scientific deep-dive

How to Take Foundayo (Orforglipron): The Practical Daily Guide for the New Oral GLP-1

Exactly how to take Foundayo, the first oral non-peptide GLP-1 approved by the FDA: titration schedule, with-or-without-food dosing, drug interactions, missed doses, contraception warning, storage, and travel.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
12 min read·8 citations

Foundayo (orforglipron) is the first oral, non-peptide GLP-1 receptor agonist approved by the FDA for chronic weight management, cleared on April 1, 2026 based on the ATTAIN-1 phase 3 trial[6][2]. Unlike the Wegovy and Zepbound injections it is a daily tablet, and unlike Rybelsus or the Wegovy tablet (both oral semaglutide) it is a small molecule rather than a peptide. The FDA label says to take it once daily, with or without food, and Lilly describes it as a pill that can be taken any time of day with no food or water restrictions[1][6]. This guide walks through exactly how to take it: the titration steps from the FDA label, the missed-dose rule, the contraceptive warning, the CYP3A4 drug-interaction rules, and what to expect as the dose goes up.

What Foundayo actually is

Foundayo is Eli Lilly's brand name for orforglipron, a small-molecule (non-peptide) GLP-1 receptor agonist taken once daily as a tablet. Because it is not a peptide, it does not require a permeation enhancer like oral semaglutide (Rybelsus) and does not need refrigeration or a cold chain[1][3]. It is approved for chronic weight management in adults with obesity or adults with overweight and at least one weight-related comorbid condition (the pivotal trial enrolled BMI ≥ 30, or BMI 27 to <30 with a comorbidity)[1]. It is one of two oral GLP-1s approved for weight management: the other, the Wegovy tablet, is oral semaglutide and keeps the empty-stomach, small-sip, 30-minute-wait rules[5]. At the top 17.2 mg dose, ATTAIN-1 participants without type 2 diabetes lost an average of 11.1% of body weight at 72 weeks versus 2.1% on placebo, per the Foundayo prescribing information[1]. The trial itself used an investigational formulation (reported as 36 mg in the NEJM paper, −11.2%) that the label presents as the equivalent 17.2 mg Foundayo dose[1][2].

The titration schedule from the FDA label

Foundayo comes in six strengths (0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg). Section 2.1 of the label requires “at least 30 days” on each dose before the next increase — slightly longer than the 4-week minimum used by weekly injectables. The first two escalations (0.8 mg to 2.5 mg, then 2.5 mg to 5.5 mg) are fixed; above 5.5 mg, the label says the dose “may be increased” to 9, 14.5 or 17.2 mg “based on treatment response and tolerability,” with 17.2 mg once daily as the maximum. The point of the slow ramp is the same as with the injectables: reduce the gastrointestinal side effects that otherwise cause people to quit[1]. For a calendar-anchored Days 1-90 walkthrough — what each dose feels like in practice, the verbatim §6 adverse-reaction rates, the missed-dose recovery rule, and what to do if your dose isn't working — see our Foundayo week-by-week titration guide.

  • Days 1-30 (at least) — 0.8 mg once daily. Starting dose. Its purpose is tolerability, not maximum weight loss.
  • Next 30+ days — 2.5 mg once daily. First required escalation.
  • Next 30+ days — 5.5 mg once daily. Second required escalation. 5.5 mg was one of the maintenance arms in the pivotal trials (−7.4% at 72 weeks in adults without diabetes)[1].
  • Optional — 9 mg once daily. May be started after at least 30 days on 5.5 mg if your prescriber judges more effect is needed and you are tolerating the drug (−8.3% at 72 weeks in the pivotal trial)[1].
  • Optional — 14.5 mg once daily. The next step up, again after at least 30 days on the prior dose[1].
  • Optional — 17.2 mg once daily (maximum). At this dose adults without type 2 diabetes lost an average of 11.1% of body weight at 72 weeks (9.6% in adults with type 2 diabetes) per the Foundayo prescribing information[1].

Magnitude comparison

Foundayo dose ladder from the FDA label — at least 30 days on each dose. 0.8 → 2.5 → 5.5 mg is required; 9, 14.5 and 17.2 mg are optional further steps based on response and tolerability. 17.2 mg is the maximum.[1]

  • Step 1 (start, ≥30 days)0.8 mg
  • Step 2 (≥30 days)2.5 mg
  • Step 3 (≥30 days)5.5 mg
  • Step 4 (optional)9.0 mg
  • Step 5 (optional)14.5 mg
  • Step 6 (optional, maximum)17.2 mg
    Label: −11.1% at 72 wk (no diabetes)
Foundayo dose ladder from the FDA label — at least 30 days on each dose. 0.8 → 2.5 → 5.5 mg is required; 9, 14.5 and 17.2 mg are optional further steps based on response and tolerability. 17.2 mg is the maximum.

The 30-day interval is a minimum, not a deadline. If you are still nauseated at the end of a step, many prescribers keep you on the current dose longer before moving up, and some patients stop at a lower dose that is working for them. Take only one tablet per day — the label says not to take more than one tablet daily[1].

Time of day and food: any time, with or without food

This is where Foundayo differs sharply from the older oral semaglutide pills (Rybelsus and the Wegovy tablet). The Foundayo prescribing information says simply to take it orally once daily, with or without food, and sets no time-of-day, fasting or water-volume rule[1]; Lilly's own materials describe it as taken any time of day with no food or water restrictions[6]. Oral semaglutide, by contrast, must be taken on an empty stomach in the morning with up to 4 ounces of plain water, followed by a wait of at least 30 minutes before eating, drinking or taking other oral medicines[4][5]. In the dedicated food-effect studies by Ma et al. 2024, exposure (AUC) and peak concentration were roughly 18–24% lower when orforglipron was taken with food than fasted, a difference the authors judged unlikely to be clinically meaningful[3]. The label likewise reports no clinically relevant food effect: with multiple doses of an investigational 37.5 mg tablet, AUC(0-24h) fell 19% and Cmax 26% with food compared with fasting[1].

The only practical guidance is the standard advice that applies to any daily medication: pick a time you will remember, consistently take it at that time, and swallow the tablet whole — the label says not to break, crush, or chew it[1]. Many patients anchor it to a daily habit they already have — first thing in the morning, with breakfast, with dinner, or at bedtime — to keep adherence high.

Drug interactions: CYP3A4 rules, simvastatin, and diabetes drugs

Orforglipron is metabolized primarily by the liver enzyme CYP3A4, so drugs that block or speed up that enzyme change how much of it reaches your bloodstream. Per Sections 2.2 and 7 of the label[1]:

  • Strong CYP3A4 inhibitors cap the dose at 9 mg once daily. In the label's interaction study, clarithromycin raised orforglipron exposure about 3.5-fold.
  • Avoid strong CYP3A4 inhibitors that also inhibit OATP1B — the label names ritonavir as the example — because they are expected to raise orforglipron levels significantly.
  • Avoid strong CYP3A4 inducers (carbamazepine cut exposure by about 82%). With moderate inducers, the label says to monitor effectiveness and escalate the dose as needed.
  • Simvastatin: do not exceed 20 mg once daily while on Foundayo (exposure to its active form roughly doubled).
  • Insulin or sulfonylureas: your prescriber may lower those doses when you start Foundayo to reduce the risk of low blood sugar.

Tell your prescriber about every prescription, OTC product, and supplement you take before starting Foundayo and at every dose change so these rules can be applied.

What to do if you miss a dose

Section 2.3 of the Foundayo prescribing information and the Medication Guide give a simple rule[1]:

  • If you miss a dose, take it as soon as possible.
  • Do not double up — the Medication Guide says not to take 2 doses in the same day or more than 1 tablet per day.
  • If you miss 7 or more doses in a row, call your prescriber: the label says to restart the dose escalation at a lower dose to reduce the risk of gastrointestinal side effects.

Note this differs from oral semaglutide (Rybelsus), whose label says to skip a missed dose and take the next one the following day[4]. Do not carry that rule over to Foundayo.

The backup contraception rule

The Foundayo prescribing information includes an important warning for women using oral hormonal contraceptives[1]. Because Foundayo delays gastric emptying and may affect the absorption of oral medications taken with it (its effect on the pill has not been tested in a clinical trial), the label advises anyone using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 30 days after starting Foundayo and for 30 days after each dose escalation (Sections 7.3 and 8.3). The label says hormonal contraceptives that are not taken by mouth (such as the patch, ring, shot, implant or hormonal IUD) should not be affected. The label also advises using effective contraception during treatment and stopping Foundayo if pregnancy occurs. Confirm the exact plan with your prescriber before starting.

What to expect as the dose goes up

  • 0.8 mg (first month). A tolerability dose. Appetite changes are usually subtle and you may not see much weight loss yet — that is expected and not a sign the drug isn't working.
  • 2.5 mg and 5.5 mg. Appetite effects become more noticeable. Gastrointestinal side effects (nausea, constipation, diarrhea, vomiting) are the most common side effects on the label, and the slow escalation exists to limit them; smaller meals, less fatty food and good hydration help[1].
  • 9 mg to 17.2 mg (optional). Higher doses produced more average weight loss in the pivotal trial (−7.4% at 5.5 mg, −8.3% at 9 mg and −11.1% at 17.2 mg over 72 weeks, versus −2.1% on placebo, in adults without diabetes), with weight loss accumulating gradually over the full 72 weeks[1][2].

Severe gastrointestinal reactions were reported in about 3% of orforglipron-treated patients versus 1% on placebo in the clinical trials, and dehydration from vomiting or diarrhea can stress the kidneys — tell your prescriber if GI symptoms are severe or won't go away[1].

For nausea management at each step the same principles that apply to injectable GLP-1s apply here — see our GLP-1 nausea management guide for the full dietary and antiemetic playbook.

Storage

Foundayo is stored at room temperature, 20-25°C / 68-77°F, with excursions permitted between 15°C and 30°C (59-86°F)[1]. No refrigeration is required. The tablets are supplied in 30-count bottles with a desiccant and a child-resistant cap[1], so keep the bottle closed, away from heat and humidity (not on a bathroom counter), and out of reach of children. This is a structural advantage over injectable pens such as Wegovy, which are labeled for refrigerated storage before first use[5].

Travel

The travel story is where oral GLP-1s really shine. Because Foundayo is a room-temperature tablet:

  • No cold chain. You can put a month of tablets in a carry-on or even a checked bag without worrying about an ice pack failing.
  • No needles, no sharps, no TSA awkwardness. Tablets pass through airport security exactly like any other prescription medication.
  • No injection routine to disrupt. Just take the daily tablet on your normal schedule, with or without food, exactly as you would at home.
  • Time zone changes: shift the dose to the new local time you plan to take it. Orforglipron's elimination half-life is roughly 29 to 49 hours[1], so a single shifted day is unlikely to meaningfully change steady-state levels. Just don't take two tablets in one day.

Foundayo vs the injectables: when oral is the right answer

Foundayo is genuinely the right first choice for some patients and a suboptimal choice for others — and if a daily pill is your preference, you can browse oral GLP-1 telehealth providers to see your options. The honest framing:

  • Choose Foundayo if: needles are a hard stop for you, you travel frequently and the cold chain is a real obstacle, you live somewhere without reliable refrigeration, you prefer a daily oral pill over a weekly injection, or you have tried injectables and discontinued for injection-site or needle reasons. If that describes you, compare orforglipron providers to find a telehealth platform that prescribes Foundayo.
  • Choose an injectable (Wegovy or Zepbound) if: you want the highest possible average weight loss (the tirzepatide SURMOUNT-1 trial produced a 20.9% mean loss at the 15 mg dose at 72 weeks[8], vs Foundayo's 11.1% at its top 17.2 mg dose[1]; these are separate trials, not a head-to-head comparison), you know you will not reliably take a daily tablet, or you are already happy on once-weekly dosing.

The 11.1% mean weight loss at Foundayo's top dose is a real, clinically meaningful number, but it is meaningfully lower than the SURMOUNT tirzepatide numbers. The trade-off is real: Foundayo buys convenience at some cost in average efficacy. Many patients will reasonably make that trade.

Foundayo is brand-only. Lilly launched it through LillyDirect with shipping from April 6, 2026, followed by retail pharmacies and telehealth providers[6]. Lilly's listed regular self-pay prices are $149 (0.8 mg), $199 (2.5 mg), $299 (5.5 mg and 9 mg) and $349 (14.5 mg and 17.2 mg) per month, with temporary reductions on the 2.5 mg ($149) and 5.5 mg ($199) doses through December 31, 2026, a $299 price on 14.5 and 17.2 mg from the first fill as long as each refill is completed within 45 days, and a savings card from $25 a month for eligible commercially insured patients[7]. Terms change, so check the current offer before you fill. If you're open to an injectable — or want a lower monthly cost — compounded semaglutide and tirzepatide from vetted telehealth providers are the most common alternative. Here are our top-scored monetized partners:

If you'd consider an injectable or compounded GLP-1 — top vetted providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

No insurance needed · HSA/FSA eligible · vetted by our editors

7.7

Ro

FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

Starting price: $149/mo (+ required membership)

Get started →Read review Ro →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Starting price: $59/mo (+ required membership)

Get started →Read review Collective →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Starting price: $79/mo (“starting at” price)

Get started →Read review CoreAge Rx →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Starting price: $79/mo (sale price)

Get started →Read review Embody →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Starting price: $129/mo (starting dose)

Get started →Read review Gala →

Bottom line

  • Foundayo is the first oral, non-peptide GLP-1 approved for weight management, dosed as a once-daily tablet: 0.8 mg, then 2.5 mg, then 5.5 mg, with optional steps to 9, 14.5 and a 17.2 mg maximum, and at least 30 days between dose increases[1].
  • The label says to take it once daily with or without food, swallowed whole — there is no morning fasting window or water rule[1][3]. This is the central practical difference from oral semaglutide (Rybelsus and the Wegovy tablet)[4][5].
  • With strong CYP3A4 inhibitors the maximum dose is 9 mg once daily; strong CYP3A4 inhibitors that also block OATP1B (such as ritonavir) and strong CYP3A4 inducers should be avoided[1]. Always reconcile your medication list with your prescriber before starting.
  • Missed a dose? Take it as soon as possible, never double up, and if you miss 7 or more doses in a row, call your prescriber to restart at a lower dose[1].
  • If you use oral hormonal contraceptives, switch to a non-oral method or add a barrier method for 30 days after starting Foundayo and for 30 days after each dose increase, per Sections 7.3 and 8.3 of the label[1].
  • Storage is room temperature with no refrigeration — a real advantage over the injectables when traveling.
  • Average weight loss at the top 17.2 mg dose was 11.1% at 72 weeks in adults without diabetes, per the FDA prescribing information[1] — meaningful, but lower than SURMOUNT tirzepatide. Pick Foundayo for convenience; pick an injectable for maximum average efficacy.

Frequently Asked Questions

Foundayo is taken as one oral tablet once daily, with or without food, swallowed whole (do not break, crush, or chew it). There is no injection, no refrigeration, and no fasting or water rule. Per the FDA label you start at 0.8 mg and stay at least 30 days on each dose: 0.8 mg, then 2.5 mg, then 5.5 mg, with optional further increases to 9, 14.5, or a 17.2 mg maximum based on response and tolerability. Always follow your prescriber's instructions and the Medication Guide that comes with your prescription.
Yes. The FDA label says Foundayo can be taken once daily with or without food, and food-effect studies found only modest, not clinically meaningful, changes in drug levels with a meal. Consistency matters more than timing — pick a daily time and stick with it.
Per the FDA label, take the missed dose as soon as possible, and do not double up — never take 2 doses in the same day or more than 1 tablet per day. If you miss 7 or more doses in a row, call your prescriber: the label says to restart the dose escalation at a lower dose to reduce the risk of gastrointestinal side effects.
Same time daily is recommended for consistency, but the FDA label does not require a specific time of day. Pick a time that fits your routine — many patients tie it to a daily anchor (morning coffee, breakfast, before bed) to make adherence easier. Consistency improves adherence more than the specific time chosen.
There is no formal contraindication, but alcohol can amplify GI side effects (nausea, gastritis) and may worsen the early-titration discomfort. Many patients on GLP-1s report reduced alcohol cravings and tolerance. If you drink, do so in moderation, especially during the first weeks. Heavy alcohol use is generally discouraged on any GLP-1.

References

  1. 1.Eli Lilly and Company. FOUNDAYO (orforglipron) tablets, for oral use — US Prescribing Information and Medication Guide. DailyMed (National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  2. 2.Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. PMID: 40960239.
  3. 3.Ma X, Liu R, Pratt EJ, Benson CT, Bhattachar SN, Sloop KW. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024. PMID: 38402332.
  4. 4.Novo Nordisk. RYBELSUS / OZEMPIC (oral semaglutide) tablets — US Prescribing Information. DailyMed (National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  5. 5.Novo Nordisk. WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets — US Prescribing Information. DailyMed (National Library of Medicine). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  6. 6.Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. PR Newswire. 2026. https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html
  7. 7.Eli Lilly and Company. Foundayo coverage and savings (self-pay pricing and savings card terms). foundayo.lilly.com. 2026. https://foundayo.lilly.com/coverage-savings
  8. 8.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.

Related research and tools

Further reading

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

Pricing Compare

Get started →
8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Read full review →

Pricing Compare

Get started →
8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

Pricing Compare

Get started →